tru Independence’s Trinity Biotech TRIB Stock Holding History

tru Independence’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-27	Closed	-$9	–	810
2020 Q2	$9	Buy	+27	New	+$6.17K	﹤0.01%	618

Other funds holding TRIB

HAIM

Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SCM

Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

tru Independence's TRIB Position: Q3 2020 in Review

tru Independence sold out of Trinity Biotech (TRIB) in Q3 2020, closing a stake of 27 shares — an estimated $9 sold.

tru Independence first reported a position in TRIB in Q2 2020 and held it in 1 quarter. The position peaked at $9 in Q2 2020. 23 funds tracked by Wall St. Rank hold TRIB as of Q3 2020.

tru Independence reported no remaining Trinity Biotech position as of Q3 2020 after selling out during the quarter.
tru Independence sold 27 Trinity Biotech shares in Q3 2020, an estimated $9.
tru Independence first reported a position in Trinity Biotech in Q2 2020 and held it in 1 quarter.
tru Independence's Trinity Biotech position peaked at $9 in Q2 2020.
23 funds tracked by Wall St. Rank held Trinity Biotech as of Q3 2020.

Based on tru Independence's 13F filing for Q3 2020, filed 19 Nov 2020.